Application of m6A related lncRNA in preparation of product for predicting prognosis of colorectal cancer
A colorectal cancer and prognosis technology, applied in the field of biomedicine, can solve the problem of not being able to distinguish the benefits of patients with poor prognosis, and achieve good predictive performance
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0036] (1) Obtaining patient information: Download early colorectal cancer RNA sequencing data (FPKM value) and corresponding clinical data, including age, gender, stage, overall survival time and survival status, from the Cancer Genome Atlas (TCGA) website. To reduce statistical bias, patients with no survival information or with a survival time of less than 3 months were excluded from further evaluation. After screening, 251 patients with early-stage colorectal cancer in the TCGA database were finally included in the analysis (see figure 1 ).
[0037](2) Acquisition of prognosis-related m6A-related lncRNAs: Using Ensembl's GTF files to distinguish mRNAs and lncRNAs in RNA-sequencing data of early colorectal cancer. Next, R software was used to extract the identified 23 m6A genes (METTTL3, METTTL14, METTTL16, WTAP, VIRMA, ZC3H13, RBM15, RBM15B, ALKBH5, FTO, YTHDC1, YTHDC2, YTHDF1, YTHDF2, YTHDF3, HNRNPC, FMR1, LRPPRC , HNRNPA2B1, IGFBP1, IGFBP2, IGFBP3, RBMX) expression dat...
Embodiment 2
[0041] Example 2 Detection of chemotherapeutic drug sensitivity
[0042] The Genomics of Cancer Drug Sensitivity (GDSC) database (https: / / cancerrxgene.org) is known to enable large-scale drug screening. Combined with genomic analysis, biomarkers of drug response can be systematically identified. Based on this database, the inventors used the "pRRophetic" package to predict the half-maximal inhibitory concentration (IC50) of commonly used chemotherapeutic drugs (camptothecin, cisplatin, rapamycin, methotrexate) in different risk groups of early-stage colorectal cancer patients ). Then, the Wilcoxon signed-rank test was used to compare the IC50 differences of different chemotherapeutic drugs in the high-risk group and the low-risk group in Example 1, and the drugs with significant differences between the groups were screened out, which were then used to guide the clinical implementation of the high-risk early stage results in the case 1 model. Postoperative chemotherapy in pat...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com